[
    {
        "id": "article-27833_245",
        "title": "Prostate Cancer -- Medical Oncology -- Aggressive Prostate Cancer",
        "content": "Aggressive disease in prostate cancer is typically defined as either locally advanced, a higher Gleason score (Gleason 4+4=8 or higher), or a rapid PSA doubling time of\u00a010 months or less. Treatment\u00a0for aggressive prostate cancers may involve radical prostatectomy, radiation therapy, HIFU, cryosurgery, hormonal therapy, chemotherapy, targeted therapy, immunotherapy, radiopharmaceuticals, or some combination of these. Early use of combinatorial therapies\u00a0is helpful in many patients presenting with aggressive or advanced, localized disease. [26] [296] [321]",
        "contents": "Prostate Cancer -- Medical Oncology -- Aggressive Prostate Cancer. Aggressive disease in prostate cancer is typically defined as either locally advanced, a higher Gleason score (Gleason 4+4=8 or higher), or a rapid PSA doubling time of\u00a010 months or less. Treatment\u00a0for aggressive prostate cancers may involve radical prostatectomy, radiation therapy, HIFU, cryosurgery, hormonal therapy, chemotherapy, targeted therapy, immunotherapy, radiopharmaceuticals, or some combination of these. Early use of combinatorial therapies\u00a0is helpful in many patients presenting with aggressive or advanced, localized disease. [26] [296] [321]"
    },
    {
        "id": "Surgery_Schwartz_11738",
        "title": "Surgery_Schwartz",
        "content": "boney structures. Modern CT PET scans have a limited role at this point.Treatment for localized prostate cancer is guided by can-cer aggressiveness and patient\u2019s preferences. Active sur-veillance is recommended for patients with low-risk disease grade 1\u20132, early-stage disease (cT1c), and small volume disease as determined by biopsy. Large prospective cohorts and randomized clinical trials have established the safety of this approach.134,135 The risk of progression to metastatic disease with close follow-up and repeat prostate biopsies is less than 2% in over 12 years. Radical prostatectomy and pelvic lymph node dissection (robotic, laparoscopic, or open), image modulated radiation therapy (IMRT), and brachytherapy are the standard of care for curative treatments. All provide equal cancer specific survival for low and intermediate risk cancers. For higher risk prostate cancer patients, both surgery and IMRT with androgen 8Figure 40-11. The da Vinci Surgical System used commonly for",
        "contents": "Surgery_Schwartz. boney structures. Modern CT PET scans have a limited role at this point.Treatment for localized prostate cancer is guided by can-cer aggressiveness and patient\u2019s preferences. Active sur-veillance is recommended for patients with low-risk disease grade 1\u20132, early-stage disease (cT1c), and small volume disease as determined by biopsy. Large prospective cohorts and randomized clinical trials have established the safety of this approach.134,135 The risk of progression to metastatic disease with close follow-up and repeat prostate biopsies is less than 2% in over 12 years. Radical prostatectomy and pelvic lymph node dissection (robotic, laparoscopic, or open), image modulated radiation therapy (IMRT), and brachytherapy are the standard of care for curative treatments. All provide equal cancer specific survival for low and intermediate risk cancers. For higher risk prostate cancer patients, both surgery and IMRT with androgen 8Figure 40-11. The da Vinci Surgical System used commonly for"
    },
    {
        "id": "Pathology_Robbins_4168",
        "title": "Pathology_Robbins",
        "content": "The relatively low rate of mortality in men with prostate cancer is related in part to increased detection of the disease through screening (discussed later), but how effective screening is at saving lives is controversial. This seeming paradox is related to the wide variation in the natural history of prostate cancer, from aggressive and rapidly fatal to indolent disease of no clinical significance. Indeed, prostate carcinoma commonly is found incidentally at autopsy in men dying of other causes, and many more men die with prostate cancer than of prostate cancer. It is not currently possible to identify the tumors that will be \u201cbad actors\u201d with certainty; thus, while some men are no doubt saved by early detection and treatment of their prostate cancers, it is equally certain that others are being \u201ccured\u201d of clinically inconsequential tumors.",
        "contents": "Pathology_Robbins. The relatively low rate of mortality in men with prostate cancer is related in part to increased detection of the disease through screening (discussed later), but how effective screening is at saving lives is controversial. This seeming paradox is related to the wide variation in the natural history of prostate cancer, from aggressive and rapidly fatal to indolent disease of no clinical significance. Indeed, prostate carcinoma commonly is found incidentally at autopsy in men dying of other causes, and many more men die with prostate cancer than of prostate cancer. It is not currently possible to identify the tumors that will be \u201cbad actors\u201d with certainty; thus, while some men are no doubt saved by early detection and treatment of their prostate cancers, it is equally certain that others are being \u201ccured\u201d of clinically inconsequential tumors."
    }
]